Approval for FOSRENOL

Approval for FOSRENOL , which controls phosphate levels in renal dialysis patients Sweden approves innovative treatment to reduce phosphate risk in patients with end stage renal failure; now FOSRENOL to enter EU mutual acknowledgement procedure Sweden’s MPA has today granted the first regulatory acceptance in the world for FOSRENOL , a non-calcium, non-aluminium phosphate binding medication developed to control phosphate amounts in renal dialysis sufferers. Sweden will now become the Reference Member Condition in the EU Mutual Acknowledgement Procedure for FOSRENOL, and this may be the first rung on the ladder in securing marketing authorization throughout Europe .

Goldman concluded, ‘Our objective is to greatly help discover and develop fresh medicines with exceptional quality and top notch scientific problem solving. Aptuit is focused on being the best-in-class provider of integrated drug discovery and development services fully, supported by a culture of scientific development and excellence.’.. Aptuit increases API capability to meet up increased demand for integrated candidate-to-IND solutions Opens 1600L/1000L reactor stream in Oxford, UK and increases API capacity in Verona, Italy Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit provides increased its global convenience of Active Pharmaceutical Ingredient Manufacture because of increased demand for API, and for its integrated and comprehensive candidate-to-IND development option.